Effects of parathyroidectomy on bone metabolism in haemodialysis patients with secondary hyperparathyroidism

References

• Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW. Chronic kidney disease: global dimension and perspectives. Lancet 2013;382:260–72.
   PubMed Web of Science ®Google Scholar
• Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int 2014;85:142–50.
   PubMed Web of Science ®Google Scholar
• Raggi P, Kleerekoper M. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008;3:836–43.
   PubMed Web of Science ®Google Scholar
• Kim SM, Long J, Montez-Rath ME, Leonard MB, Norton JA, Chertow GM. Rates and outcomes of parathyroidectomy for secondary hyperparathyroidism in the United States. Clin J Am Soc Nephrol 2016;11:1260–7.
   PubMed Web of Science ®Google Scholar
• Tominaga Y, Matsuoka S, Uno N, Sato T. Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics. Ther Apher Dial 2008;12 Suppl 1:S21–S6.
   PubMed Web of Science ®Google Scholar
• Yajima A, Inaba M, Tominaga Y, Ito A. Bone formation by minimodeling is more active than remodeling after parathyroidectomy. Kidney Int 2008;74:775–81.
   PubMed Web of Science ®Google Scholar
• Komaba H, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Fukagawa M. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 2015;88:350–9.
   PubMed Web of Science ®Google Scholar
• Trunzo JA, McHenry CR, Schulak JA, Wilhelm SM. Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism. Surgery 2008;144:915–18; discussion 9.
   PubMed Web of Science ®Google Scholar
• Evenepoel P, Claes K, Kuypers D, Maes B, Vanrenterghem Y. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transplant 2005;20:1714–20.
   PubMed Web of Science ®Google Scholar
• Ishani A, Liu J, Wetmore JB, Lowe KA, Do T, Bradbury BD, Block GA, Collins AJ. Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol 2015;10:90–7.
   Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int Suppl 2009;(113):S1–130. doi:10.1038/ki.2009.188
   Web of Science ®Google Scholar
• Bellido T, Saini V, Pajevic PD. Effects of PTH on osteocyte function. Bone 2013;54:250–7.
   PubMed Web of Science ®Google Scholar
• West SL, Lok CE, Langsetmo L, Cheung AM, Szabo E, Pearce D, Fusaro M, Wald R, Weinstein J, Jamal SA. Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res 2015;30:913–19.
   PubMed Web of Science ®Google Scholar
• Yajima A, Ogawa Y, Takahashi HE, Tominaga Y, Inou T, Otsubo O. Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism. Am J Kidney Dis 2003;42:729–38.
   PubMed Web of Science ®Google Scholar
• Komaba H, Kakuta T, Fukagawa M. Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol 2011;15:797–809.
   PubMed Web of Science ®Google Scholar
• Couttenye MM, D'haese PC, Van Hoof VO, Lemoniatou E, Goodman W, Verpooten GA, De Broe ME. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996;11:1065–72.
   PubMed Web of Science ®Google Scholar
• Morishita T, Nomura M, Hanaoka M, Saruta T, Matsuo T, Tsukamoto Y. A new assay method that detects only intact osteocalcin. Two-step non-invasive diagnosis to predict adynamic bone disease in haemodialysed patients. Nephrol Dial Transplant 2000;15:659–67.
   PubMed Web of Science ®Google Scholar
• Ueda M, Inaba M, Okuno S, Nagasue K, Kitatani K, Ishimura E, Shimizu M, Miki T, Kim M, Nishizawa Y. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 2002;40:802–9.
   PubMed Web of Science ®Google Scholar
• Chen JS, Sambrook PN, March L, Cameron ID, Cumming RG, Simpson JM, Seibel MJ. Hypovitaminosis D and parathyroid hormone response in the elderly: effects on bone turnover and mortality. Clin Endocrinol (Oxf) 2008;68:290–8.
   PubMed Web of Science ®Google Scholar
• Covic A, Passlick-Deetjen J, Kroczak M, Buschges-Seraphin B, Ghenu A, Ponce P, Marzell B, de Francisco AL. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant 2013;28:2383–92.
   PubMed Web of Science ®Google Scholar
• Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone 2005;37:148–58.
   PubMed Web of Science ®Google Scholar
• Costa AG, Cremers S, Rubin MR, McMahon DJ, Sliney J Jr, Lazaretti-Castro M, Silverberg SJ, Bilezikian JP. Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab 2011;96:3804–10.
   PubMed Web of Science ®Google Scholar
• Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 2011;6:e25900.
   PubMed Web of Science ®Google Scholar
• Otero K, Shinohara M, Zhao H, Cella M, Gilfillan S, Colucci A, Faccio R, Ross FP, Teitelbaum SL, Takayanagi H, Colonna M. TREM2 and beta-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunol 2012;188:2612–21.
   PubMed Web of Science ®Google Scholar
• Cejka D, Jager-Lansky A, Kieweg H, Weber M, Bieglmayer C, Haider DG, Diarra D, Patsch JM, Kainberger F, Bohle B, Haas M. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012;27:226–30.
   PubMed Web of Science ®Google Scholar
• Ishimura E, Okuno S, Ichii M, Norimine K, Yamakawa T, Shoji S, Nishizawa Y, Inaba M. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J Clin Endocrinol Metab 2014;99:4315–20.
   PubMed Web of Science ®Google Scholar
• Barnas U, Schmidt A, Seidl G, Kaider A, Pietschmann P, Mayer G. A comparison of quantitative computed tomography and dual X-ray absorptiometry for evaluation of bone mineral density in patients on chronic hemodialysis. Am J Kidney Dis 2001;37:1247–52.
   PubMed Web of Science ®Google Scholar
• Fontaine MA, Albert A, Dubois B, Saint-Remy A, Rorive G. Fracture and bone mineral density in hemodialysis patients. Clin Nephrol 2000;54:218–26.
   PubMed Web of Science ®Google Scholar
• Ambrus C, Almasi C, Berta K, Deak G, Marton A, Molnar MZ, Nemeth Z, Horvath C, Lakatos P, Szathmari M, Mucsi I. Bone mineral density and parathyroid function in patients on maintenance hemodialysis. Int Urol Nephrol 2011;43:191–201.
   PubMed Web of Science ®Google Scholar
• Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis 2007;49:674–81.
   PubMed Web of Science ®Google Scholar
• Yenchek RH, Ix JH, Shlipak MG, Bauer DC, Rianon NJ, Kritchevsky SB, Harris TB, Newman AB, Cauley JA, Fried LF, Health A. Body Composition S. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 2012;7:1130–6.
   PubMed Web of Science ®Google Scholar
• Malluche HH, Davenport DL, Cantor T, Monier-Faugere MC. Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis. Clin J Am Soc Nephrol 2014;9:1254–62.
   PubMed Web of Science ®Google Scholar
• Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011;6:913–21.
   PubMed Web of Science ®Google Scholar
• Llach F, Velasquez Forero F. Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 2001;38:S20–S33.
   PubMed Web of Science ®Google Scholar
• Coen G. Calcimimetics, parathyroid hormone, and vascular calcification in chronic kidney disease. Kidney Int 2008;74:1229–31.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalantar-Zadeh K, Ahmadzadeh S. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Am J Kidney Dis 2012;59:58–66.
   PubMed Web of Science ®Google Scholar
• Torres PA, De Broe M. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease. Kidney Int 2012;82:19–25.
   PubMed Web of Science ®Google Scholar
• Bover J, Urena P, Ruiz-Garcia C, daSilva I, Lescano P, del Carpio J, Ballarin J, Cozzolino M. Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 2016;11:161–74.
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208–18.
   PubMed Web of Science ®Google Scholar
• Bleyer AJ, Burkart J, Piazza M, Russell G, Rohr M, Carr JJ. Changes in cardiovascular calcification after parathyroidectomy in patients with ESRD. Am J Kidney Dis 2005;46:464–9.
   PubMed Web of Science ®Google Scholar
• Ivarsson KM, Akaberi S, Isaksson E, Reihner E, Rylance R, Prutz KG, Clyne N, Almquist M. The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism. Nephrol Dial Transplant 2015;30:2027–33.
   PubMed Web of Science ®Google Scholar